JP2023517043A5 - - Google Patents

Info

Publication number
JP2023517043A5
JP2023517043A5 JP2022553213A JP2022553213A JP2023517043A5 JP 2023517043 A5 JP2023517043 A5 JP 2023517043A5 JP 2022553213 A JP2022553213 A JP 2022553213A JP 2022553213 A JP2022553213 A JP 2022553213A JP 2023517043 A5 JP2023517043 A5 JP 2023517043A5
Authority
JP
Japan
Prior art keywords
compound
substituted
salt according
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022553213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517043A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/051764 external-priority patent/WO2021176366A1/en
Publication of JP2023517043A publication Critical patent/JP2023517043A/ja
Publication of JP2023517043A5 publication Critical patent/JP2023517043A5/ja
Pending legal-status Critical Current

Links

JP2022553213A 2020-03-06 2021-03-03 ヒト免疫不全ウイルスの複製阻害剤 Pending JP2023517043A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062985937P 2020-03-06 2020-03-06
US62/985,937 2020-03-06
US202063040051P 2020-06-17 2020-06-17
US63/040,051 2020-06-17
PCT/IB2021/051764 WO2021176366A1 (en) 2020-03-06 2021-03-03 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2023517043A JP2023517043A (ja) 2023-04-21
JP2023517043A5 true JP2023517043A5 (cg-RX-API-DMAC7.html) 2024-03-13

Family

ID=74859494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022553213A Pending JP2023517043A (ja) 2020-03-06 2021-03-03 ヒト免疫不全ウイルスの複製阻害剤

Country Status (12)

Country Link
US (1) US20230355626A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114834A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023517043A (cg-RX-API-DMAC7.html)
KR (1) KR20220151655A (cg-RX-API-DMAC7.html)
CN (1) CN115551858A (cg-RX-API-DMAC7.html)
AU (2) AU2021231447A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017832A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170536A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002405A1 (cg-RX-API-DMAC7.html)
IL (1) IL296182A (cg-RX-API-DMAC7.html)
MX (1) MX2022011016A (cg-RX-API-DMAC7.html)
WO (1) WO2021176366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
US12703699B2 (en) 2020-03-06 2026-08-11 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US10035760B2 (en) 2013-10-24 2018-07-31 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2016250662A1 (en) 2015-04-23 2017-11-16 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
PT3286166T (pt) 2015-04-23 2020-08-18 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
WO2020058844A1 (en) * 2018-09-20 2020-03-26 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2969030T3 (es) * 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
US20210395248A1 (en) * 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP2022506399A (ja) * 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP3986561B1 (en) * 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir

Similar Documents

Publication Publication Date Title
AU2020348685B2 (en) IL-17A modulators and uses thereof
JP7580136B2 (ja) Jak阻害剤化合物及びその使用
US20260028329A1 (en) Jak1 selective inhibitors
WO2025053850A1 (en) Covalent kras-binding compounds for medical treatment
CN102164912B (zh) 制备喹诺酮类化合物的工艺
JP7222590B2 (ja) 3-アザビシクロ[3,1,1]ヘプタン誘導体及びこれを含む薬学的組成物
JP2023509495A (ja) RORγt阻害剤、その製造方法及び使用
JP2012509309A (ja) Faah阻害剤としての1−オキサ−8−アザスピロ[4.5]デカン−8−カルボキサミド化合物
EP3102572A1 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN105228620A (zh) 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物
JP2009526037A (ja) トリアゾロピリジン化合物
JP2014530207A (ja) 縮合環を有するオキサゾリドン(oxazolidone)類の抗菌物質
WO2023283453A1 (en) Phenyl acetamide based il-17a modulators and uses thereof
JP2022551256A5 (cg-RX-API-DMAC7.html)
KR20190129034A (ko) 금속효소 억제제 화합물
JP2022551254A5 (cg-RX-API-DMAC7.html)
JP2023517312A5 (cg-RX-API-DMAC7.html)
WO2021064677A1 (en) Inhibitors of human immunodeficiency virus replication
IL296182A (en) Inhibitors of human immunodeficiency virus replication
JP2025515833A5 (cg-RX-API-DMAC7.html)
WO2022217118A1 (en) Pyrimidine based ras modulators and uses thereof
JP7168245B2 (ja) 三環式化合物
JP2022541772A (ja) インターロイキンの調節におけるプロドラッグ
CA3253274A1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECIPIENT
WO2019042442A1 (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物